Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?

Cancer

Volumn 116, Issue 13, 2010, Pages 3093-3101

  Ragage, Florence ^a   Debled, Marc ^a   MacGrogan, Gaëtan ^a   Brouste, Véronique ^a   Desrousseaux, Marie ^a   Soubeyran, Isabelle ^a   De Lara, Christine Tunon ^a   Mauriac, Louis ^a   De Mascarel, Isabelle ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Breast cancer; Lymph node positive; Lymphovascular invasion; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; PROGNOSIS;

EID: 77954256274     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25137     Document Type: Article

References (18)

1. de Mascarel I, Bonichon F, Durand M, et al. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer. 1998;34:58-65. (Pubitemid 28123381)
2. Davis BW, Gelber R, Goldhirsch A, et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol. 1985;16:1212-1218; erratum 1987;18:79.
3. Truong PT, Berthelet E, Lee J, Kader HA, Olivotto IA. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with 1 to 3 positive axillary lymph nodes. Cancer. 2005;103:2006-2014. (Pubitemid 40605106)
4. Yildirim E, Berberoglu U. Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg. 2007;31:276-289. (Pubitemid 46183511)
5. Colleoni M, Rotmensz N, Maisonneuve P, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol. 2007;18:1632-1640.
6. MacGrogan G, Desrousseaux M, de Mascarel I, et al. Prognostic value of Mib1 in a tissue microarray of 855 invasive breast carcinomas. 5th European Breast Cancer Conference, March 21-25, 2006 (Nice, France) [abstract]. Eur J Cancer. 2006;4(suppl):123-124. Abstract 261.
7. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathology. 1991;19:403-410.
8. Rosen PP, Oberman HA. Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology; 1993.
9. de Mascarel I, MacGrogan G, Debled M, et al. D2-40 in breast cancer: should we detect more vascular emboli? Mod Pathol. 2009;22:216-222.
10. Braun M, Flucke U, Debald M, et al. Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases. Breast Cancer Res Treat. 2008;112:503-511.
11. Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol. 2007;20:183-191. (Pubitemid 46422172)
12. Ejlertsen B, Jensen MB, Rank F, et al on behalf of the Danish Breast Cancer Cooperative Group. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer Inst. 2009;101:729-735.
13. Mohammed RA, Martin SG, Gill MS, et al. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol. 2007;31:1825-1833.
14. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg. 2000;191:1-6.
15. Goldhirsch A, Coates AS, Gelber RD, et al. First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol. 2006;17:1772-1776.
16. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26:4063-4071.
17. Dowsett M, Cuzick J, Wales C, et al on behalf of the ATAC Trialists. Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study [abstract]. Breast Cancer Res Treat. 2008;107(suppl):1. Abstract 53.
18. Sun Y, Goodison S, Li J, Liu L, Farmerie W. Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics. 2007;23:30-37. (Pubitemid 46017852)